SCHEMBL6320717

SCHEMBL6320717

CCCCC=Cc1ccc(Cc2c(C)[nH]c3ccc(C(=O)NS(=O)(=O)c4ccc(C)cc4)cc23)c(Cl)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 4/20 0.38
LGALS8 O00214 1/20 0.36
LGALS3 P17931 1/20 0.36
MAPT P10636 2/20 0.35
BCL2L1 Q07817 1/20 0.35
MCL1 Q07820 1/20 0.35
HDAC3 O15379 2/20 0.35
HDAC4 P56524 2/20 0.35
HDAC1 Q13547 2/20 0.35
HDAC7 Q8WUI4 2/20 0.35
HDAC2 Q92769 2/20 0.35
HDAC10 Q969S8 2/20 0.35
HDAC11 Q96DB2 2/20 0.35
HDAC8 Q9BY41 2/20 0.35
HDAC6 Q9UBN7 2/20 0.35
HDAC9 Q9UKV0 2/20 0.35
HDAC5 Q9UQL6 2/20 0.35
FLT1 P17948 3/20 0.35
FLT4 P35916 3/20 0.35
KDR P35968 3/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6320714 1.00 PTGS2 (0.38) PTGS2LGALS8LGALS3MAPTBCL2L1
SCHEMBL6326527 0.88 PTGS2 (0.44) PTGS2MAPTMCL1HDAC3HDAC4
SCHEMBL6321853 0.88 PPARG (0.42) PTGS2MAPTMCL1TDP1
SCHEMBL6321859 0.88 PPARG (0.42) PTGS2MAPTMCL1TDP1
SCHEMBL6321835 0.84 PTPN5 (0.46) PTGS2MAPTGAAALDH1A1CYP2C9
SCHEMBL6320828 0.84 PTPN5 (0.46) PTGS2MAPTGAAALDH1A1CYP2C9
SCHEMBL5881768 0.84 FLT1 (0.51) PTGS2MAPTHDAC3HDAC4HDAC1
SCHEMBL6327087 0.84 PTGS2 (0.39) PTGS2LGALS8LGALS3MAPTBCL2L1
SCHEMBL6320006 0.83 MEN1 (0.45) MAPTGAAALDH1A1LMNATDP1
SCHEMBL6322504 0.83 MEN1 (0.45) MAPTGAAALDH1A1LMNATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050171185-A1 Indole derivatives FUJISAWA PHARMACEUTICAL CO., LTD., A JAPANESE CORPORATION 2005-08-04 US claimed
EP-1070705-A1 INDOLE DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-01-24 EP claimed
US-20050171185-A1 Indole derivatives FUJISAWA PHARMACEUTICAL CO., LTD., A JAPANESE CORPORATION 2005-08-04 US disclosed
EP-1070705-A1 INDOLE DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-01-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050171185-A1 Indole derivatives PDE5A, IGFBP5, HTR5A PTGS2 2111/4885LGALS8 657/4885LGALS3 547/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.